The Researcher OG

Directions Website

The Researcher OG Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from The Researcher OG, Alternative & holistic health service, Santa Barbara, CA.

Mike Robinson, Researcher OG
Ask for a Free ECS Consult

Creator of Researcher®️ Genevieve's Dream™️ Nano Terps®️ Thermonoids®️ GENEVEX®️ Plant Chat®️ PREVENT®️ Get Balanced®️ NANO®️ Jane®️ & more

CEO Nanobles/Global Cannabinoid Research Center GCRC

An analytical study published in September 2026, titled Determination of cadmium, lead and mercury in cannabis flowers b...
10/15/2026

An analytical study published in September 2026, titled Determination of cadmium, lead and mercury in cannabis flowers by microwave plasma atomic emission spectrometry, evaluates a potentially less costly method for testing cannabis flowers for three toxic metals.

Researchers prepared samples through acid digestion and measured cadmium and lead using microwave plasma atomic emission spectrometry. Mercury required an additional cold-vapor step. The team validated the methods using reference materials and samples with known amounts of added metals.

The team applied the testing to 30 commercial cannabis flower samples. The method did not detect cadmium or mercury in that sample set, while it quantified lead. Detection depends on the method’s sensitivity, so a result reported as not detected doesn't mean an element is absent at every possible concentration.

The reported accuracy and precision support the method’s use for the elements and sample preparation evaluated. However, a validated laboratory method and a compliant product are different questions. A result must still be compared with the relevant standard for the product and its intended use.

For the cannabis industry, reliable contaminant testing supports confidence in the supply chain. The plant’s chemistry cant tell us whether it picked up metals from soil, water, or processing equipment, and appearance wont answer that question either.

This research contributes a measurement tool that could make routine quality control more accessible without assuming every laboratory method is interchangeable.

Mike Robinson, Global Cannabinoid Research Center (GCRC)


https://lnkd.in/g8fdMkQb

An animal study published in September 2026, entitled "Studying Peripheral Neuropathy and Associated Neuropathic Pain in...
10/15/2026

An animal study published in September 2026, entitled "Studying Peripheral Neuropathy and Associated Neuropathic Pain in HIV-1 Transgenic Rats: Evaluation of the Therapeutic Effect of Cannabidiol and Beta-Caryophyllene", compares C*D with beta-caryophyllene, a plant terpene, in a model of HIV-related nerve pain.

Researchers used rats expressing HIV-related proteins and examined nerve tissue, immune activity, and pain-like behavior. The animals showed loss of small nerve fibers in the skin, greater immune cell infiltration around sensory nerve structures, and increased sensitivity to normally non-painful touch.Both the model and the compound comparisons are relevant to understanding neuropathy.

In the experiments reported, beta-caryophyllene produced greater relief of pain-like behavior than C*D. Protein analysis also identified changes associated with the terpene’s effects, giving researchers additional mechanisms to investigate.This was a controlled animal experiment, not a trial in people living with HIV.

A compound performing better in rats doesn't establish the best treatment, dose, or formulation for a patient. It also doesnt show that ordinary exposure to a terpene through food or cannabis aroma would reproduce the experimental effect.

The work supports treating terpenes as biologically active research candidates rather than decorative ingredients. Beta-caryophyllene deserves further investigation for this specific form of nerve pain, including how its effects relate to immune and sensory signaling.

Clinical research will be needed to determine whether those findings translate into dependable benefits for people.

Mike Robinson, Global Cannabinoid Research Center



https://www.mdpi.com/1999-4923/18/9/1176

A laboratory study published online in June 2026, entitled "Synergistic potential between camphene, myrcene, and ceftazi...
10/15/2026

A laboratory study published online in June 2026, entitled "Synergistic potential between camphene, myrcene, and ceftazidime against medically important bacteria", investigates whether two plant terpenes can improve an antibiotic’s activity against selected bacteria.

Researchers tested myrcene, camphene, their combination, and combinations with ceftazidime against 14 bacterial strains. They measured the concentrations needed to inhibit growth and used combination testing to assess whether the ingredients worked better together.

The effects depended on the organism. Myrcene inhibited selected Pseudomonas and Acinetobacter strains, while camphene showed activity against Staphylococcus aureus. Adding the terpenes to ceftazidime reduced the amount of antibiotic needed to inhibit six strains, with an eightfold improvement reported for one Acinetobacter comparison.

Measurements of material released from bacterial cells suggested that changes to the cell membrane contributed to the effect. The tested terpenes didn't cause red blood cell breakdown in the laboratory assay, although that single safety measurement doesn't establish a safe dose or treatment in people.

This is an interesting example of examining terpenes as formulation partners rather than assuming their role ends with aroma. It also shows why the organism, concentration, and combination matter. The results support further antimicrobial development, but they don't justify using terpene products to replace prescribed antibiotics or predict that the same combination will work against every infection.

Mike Robinson, Global Cannabinoid Research Center



https://www.cabidigitallibrary.org/doi/full/10.5555/20260481326

A university report dated September 2026, entitled "Methods of Harvest and Compositional Characterization of H**p Fibers...
10/14/2026

A university report dated September 2026, entitled "Methods of Harvest and Compositional Characterization of H**p Fibers From Medical Cannabis Biomass Using Detergent Fiber Analysis", explores a useful second use for stems left after medical cannabis production. Researchers compared two fiber-recovery approaches and examined whether the fibers resembled industrial h**p material.

The work used water retting, a process that helps separate fibers from surrounding stem tissues. Both harvesting approaches produced usable fibers, though one yielded cleaner material after shorter retting periods, while the other offered greater potential for large-scale processing. Longer retting improved separation and increased the cellulose fraction as non-cellulosic components decreased.

To assess composition, researchers used detergent fiber analysis to estimate cellulose, hemicellulose, and lignin fractions. These are structural components of plant tissue, and measuring them gives a more useful description of the recovered material than simply calling it cannabis fiber. The water-retted fibers had compositions comparable to well-retted industrial h**p fibers.

The report points to applications such as cement-based composites, but compositional similarity doesn't mean every building product made from the fibers will perform equally well. Strength, durability, processing conditions, and compatibility with other ingredients still need testing in the finished material.

This is a practical example of looking beyond the harvested flower. A medical cannabis crop can leave valuable structural material behind, and a standardized way to recover and assess it can support further product development. The opportunity is to turn a discarded stem into a characterized raw material, rather than assume that all leftover biomass has the same quality.

Mike Robinson, Global Cannabinoid Research Center



https://digitalcommons.usu.edu/cgi/viewcontent.cgi?article=1008&context=cpl_pubs

A master's thesis dated July 2026, entitled "Using Plant-Derived Natural Molecules to Manage Fungal Pathogens", investig...
10/14/2026

A master's thesis dated July 2026, entitled "Using Plant-Derived Natural Molecules to Manage Fungal Pathogens", investigates botanical compounds as possible tools for managing crop disease. The university's public abstract describes laboratory and plant experiments, although the full thesis is under embargo and wasn't available for this review.

The research reports that selected flavonoids and terpenes suppressed fungal growth and disease development, including gray mold caused by Botrytis cinerea and a strawberry disease involving Neopestalotiopsis species. A fatty acid also showed activity against the organism responsible for southern blight. These are agricultural findings, rather than evidence that the same materials treat fungal infections in people.

The work also explored how the compounds might act. Researchers used a protein-stability method to identify candidate fungal proteins that interact with selected molecules, pointing to metabolic processes that could be disrupted. Some treatments appeared to prime plant defenses, meaning the plant was better prepared to respond to a later infection.

A result on a laboratory plate and a result on an infected plant answer different questions. The first can reveal direct antifungal activity, while the second shows how the treatment behaves in living plant tissue. Both help build the case for a useful crop-protection approach.

That combination is interesting because crop protection can involve both affecting the pathogen and strengthening the host's response. The public abstract doesn't provide enough detail to recommend a spray concentration or treatment schedule for h**p. It supports further investigation of specific plant compounds, but growers can't rely on them until effectiveness, crop compatibility, and field performance are established.

Mike Robinson, Global Cannabinoid Research Center



https://repository.lsu.edu/gradschool_theses/6432/

A study published in September 2026, entitled The anterior cingulate cortex mediates cisplatin-induced mechanical allody...
10/13/2026

A study published in September 2026, entitled The anterior cingulate cortex mediates cisplatin-induced mechanical allodynia and represents a target for cannabigerol antinociception, investigates CBG in a mouse model of chemotherapy-related nerve pain.

Researchers examined a brain region involved in pain processing, asking whether it helps maintain sensitivity after cisplatin treatment and whether CBG can act there. Adult male mice received cisplatin over four weeks and developed mechanical allodynia, meaning that normally nonpainful touch produced a pain-related response.

CBG given by injection reduced that sensitivity without changing baseline thresholds in mice that hadnt developed neuropathy. Selectively inhibiting neurons in the anterior cingulate cortex also reduced sensitivity, supporting the regions involvement in the pain state.

Researchers then delivered small amounts of CBG directly into that brain region and observed temporary reductions in sensitivity. Together, the experiments support the anterior cingulate cortex as one site where CBG can influence this particular pain response.

They don't establish which receptor fully explains the effect or that CBG repairs the damaged nerves.Pain-related behavior can change without proving that the original nerve injury has healed.

Separating symptom relief from tissue repair gives this result clearer meaning and helps define what a follow-up experiment should measure before claiming clinical benefit.The value is in connecting a cannabinoid response with a specific pain circuit.

These were male mice and experimental delivery methods, so the results don't provide a human dosing plan. They do give researchers a more focused direction for studying how CBG might help address neuropathic pain after chemotherapy.

Mike Robinson, Global Cannabinoid Research Center



https://journals.sagepub.com/doi/full/10.1177/17448069261491110

A scientific review published online in September 2026, titled "Bias from within: intracellular allosterism and the ICL2...
10/13/2026

A scientific review published online in September 2026, titled "Bias from within: intracellular allosterism and the ICL2 hub", examines how drugs might influence receptors from the inside of a cell. It focuses on G protein-coupled receptors, a large family that includes cannabinoid receptors, and the structures that help determine which signals a receptor sends.

Most people hear that a molecule activates a receptor and picture a simple switch. In reality, an activated receptor can engage different signaling partners. The review describes an internal pocket around the second intracellular loop (ICL2) as an important site for controlling these interactions. Binding at this alternative site is called allosteric modulation, meaning a molecule changes receptor behavior from a site other than the usual binding site.

The authors bring together structural and mechanistic work suggesting that this approach could favor particular signaling pathways. They also discuss practical obstacles, including whether a molecule can reach the site, how it behaves in the body, and whether findings transfer between species.

This is also why two molecules acting at the same receptor can produce different results. The receptor's shape, available signaling partners, and interaction site all shape the response. Drug development becomes more informative when it measures those differences.

For cannabinoid science, the broader lesson is that receptor activation alone doesn't describe the full biological response. Which pathway follows activation can matter just as much. This review outlines a drug-discovery strategy, rather than demonstrating that a cannabis product already provides this degree of control in patients.

Mike Robinson, Global Cannabinoid Research Center



https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(26)00227-0

A study published in September 2026, entitled "Cannabis and Alcohol Prepartying Among Young Adults: Daily-Level Associat...
10/12/2026

A study published in September 2026, entitled "Cannabis and Alcohol Prepartying Among Young Adults: Daily-Level Associations with Cannabis Intoxication and Simultaneous Alcohol and Cannabis Use", examines what happens when young adults use cannabis or alcohol before going to a social event. Researchers followed adults aged 18 to 25 through repeated daily reporting periods, allowing them to compare a person's pre-party days with that same person's other substance-use days.

Cannabis prepartying was associated with spending more hours high, reporting greater intoxication, and using cannabis and alcohol during overlapping periods. That last point matters because simultaneous use means both substances' effects are present together, rather than simply reporting both sometime during the same month. Cannabis prepartying occurred on about 16% of cannabis-use days in the sample.

The findings don't establish that prepartying caused those outcomes. Plans for a longer evening, social surroundings, or other day-to-day differences could also contribute. However, comparing someone with themselves helps researchers look beyond a simple comparison between heavier and lighter users.

For public education, this offers a useful way to discuss use circumstances without reducing everything to a product or a percentage on its label. When someone starts using before the main event, the timing and the possibility of adding alcohol become part of understanding that evening's exposure.

Mike Robinson, Global Cannabinoid Research Center



https://www.jsad.com/doi/abs/10.15288/jsad.26-00193

In a new 2026 study, researchers compared a C*D-rich h**p leaf extract with isolated C*D to see how each affected adult ...
10/12/2026

In a new 2026 study, researchers compared a C*D-rich h**p leaf extract with isolated C*D to see how each affected adult female Aedes aegypti mosquitoes. They weren’t simply asking whether h**p could keep mosquitoes away; they separately tested whether it killed mosquitoes after direct application, discouraged blood feeding, or repelled them through the air.

The h**p extract caused more deaths as the applied dose increased, and its median lethal dose was 22.13 micrograms per mosquito after 24 hours. When researchers tested C*D alone at amounts matching the C*D in the extract, it produced less mortality. The extract also discouraged feeding more effectively than isolated C*D.

However, the extract didn’t repel mosquitoes in the airborne test, which helps explain why we shouldn’t describe every feeding deterrent as something that keeps mosquitoes away from a distance. Different tests measure different behaviors, and those distinctions matter when researchers consider potential products.

Overall, C*D didn’t fully explain the extract’s activity against adult mosquitoes. Other plant compounds appear to contribute, but this experiment doesn’t identify which ones are responsible or show that they act synergistically. It’s an example of why testing the whole mixture alongside individual ingredients can reveal information that a C*D percentage alone won’t provide.

These laboratory results also don’t establish that h**p extract is safe or effective as a repellent applied to human skin.

Mike Robinson, Global Cannabinoid Research Center


Toxic and repellent effects of h**p leaf extracts and cannabidiol against adult female yellow fever mosquitoes, Aedes aegypti
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354696

Address

Santa Barbara, CA

Opening Hours

Monday 10am - 6pm
Tuesday 7am - 5pm
Wednesday 7am - 5pm
Thursday 2pm - 10pm
Friday 2pm - 10pm
Saturday 10am - 5pm
Sunday 6pm - 10pm

Website

, ,

Alerts

Be the first to know and let us send you an email when The Researcher OG posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category